X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE PIRAMAL ENTERPRISES SUVEN LIFE/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 16.0 8.5 188.0% View Chart
P/BV x 3.2 1.5 210.7% View Chart
Dividend Yield % 0.7 1.1 66.4%  

Financials

 SUVEN LIFE   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    SUVEN LIFE
Mar-18
PIRAMAL ENTERPRISES
Mar-18
SUVEN LIFE/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs2513,083 8.1%   
Low Rs1551,902 8.1%   
Sales per share (Unadj.) Rs49.1589.7 8.3%  
Earnings per share (Unadj.) Rs9.7284.0 3.4%  
Cash flow per share (Unadj.) Rs11.4310.5 3.7%  
Dividends per share (Unadj.) Rs1.5025.00 6.0%  
Dividend yield (eoy) %0.71.0 73.7%  
Book value per share (Unadj.) Rs60.31,467.0 4.1%  
Shares outstanding (eoy) m127.28180.27 70.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.14.2 97.7%   
Avg P/E ratio x20.98.8 237.9%  
P/CF ratio (eoy) x17.88.0 221.9%  
Price / Book Value ratio x3.41.7 198.1%  
Dividend payout %15.48.8 175.4%   
Avg Mkt Cap Rs m25,825449,332 5.7%   
No. of employees `0001.16.8 15.7%   
Total wages/salary Rs m61319,881 3.1%   
Avg. sales/employee Rs Th5,832.615,535.6 37.5%   
Avg. wages/employee Rs Th571.52,905.4 19.7%   
Avg. net profit/employee Rs Th1,153.87,482.5 15.4%   
INCOME DATA
Net Sales Rs m6,253106,310 5.9%  
Other income Rs m2332,595 9.0%   
Total revenues Rs m6,485108,906 6.0%   
Gross profit Rs m1,98251,599 3.8%  
Depreciation Rs m2134,773 4.5%   
Interest Rs m4629,783 0.2%   
Profit before tax Rs m1,95519,638 10.0%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m718-28,764 -2.5%   
Profit after tax Rs m1,23751,203 2.4%  
Gross profit margin %31.748.5 65.3%  
Effective tax rate %36.7-146.5 -25.1%   
Net profit margin %19.848.2 41.1%  
BALANCE SHEET DATA
Current assets Rs m5,622118,154 4.8%   
Current liabilities Rs m1,168462,260 0.3%   
Net working cap to sales %71.2-323.7 -22.0%  
Current ratio x4.80.3 1,883.9%  
Inventory Days Days8127 306.4%  
Debtors Days Days3647 77.2%  
Net fixed assets Rs m3,325113,727 2.9%   
Share capital Rs m127361 35.3%   
"Free" reserves Rs m7,547264,093 2.9%   
Net worth Rs m7,674264,454 2.9%   
Long term debt Rs m14242,206 0.0%   
Total assets Rs m9,135726,834 1.3%  
Interest coverage x43.21.7 2,605.0%   
Debt to equity ratio x00.9 0.2%  
Sales to assets ratio x0.70.1 467.9%   
Return on assets %14.011.1 126.1%  
Return on equity %16.119.4 83.2%  
Return on capital %26.010.3 252.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,06615,110 33.5%   
Fx outflow Rs m2,0014,298 46.6%   
Net fx Rs m3,06510,813 28.3%   
CASH FLOW
From Operations Rs m699-159,666 -0.4%  
From Investments Rs m-6-17,677 0.0%  
From Financial Activity Rs m-577186,503 -0.3%  
Net Cashflow Rs m1169,364 1.2%  

Share Holding

Indian Promoters % 63.4 52.9 119.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 4.0 -  
FIIs % 0.0 26.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 16.5 221.2%  
Shareholders   37,287 93,274 40.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   STERLING BIOTECH  NOVARTIS  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare SUVEN LIFE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 134 Points Lower; Metal and Telecom Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended marginally lower. Sectoral indices ended on a mixed note with stocks.

Related Views on News

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

This Trend Will Produce a Once in a Lifetime Opportunity to Buy Stocks(The 5 Minute Wrapup)

Jan 15, 2019

Unlike his habit of pouring out stock wisdom in his annual letters to shareholders, Buffett spoke of this trend only once every few decades.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

My Next Small Cap Recommendation Is Practically a 'No Brainer'(Profit Hunter)

Jan 14, 2019

With a strong debt free balance sheet in its favour, attractive dividends and trading at almost lifetime lows, this investing idea is almost a no brainer.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Jan 22, 2019 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE 8-QTR ANALYSIS

COMPARE SUVEN LIFE WITH

MARKET STATS